Opko

Opko Health said this week that is has begun a multi-center clinical validation study to support the launch of its 4Kscore protein biomarker prostate cancer test.

Opko Health announced this week that it has appointed David Okrongly president of its diagnostics business unit.

Title: Compositions and Methods for Selective Inhibition of VEGF
Patent Number: 8,470,792
Filed: Dec. 4, 2009
Lead Inventor: Phillip Frost, Opko Health (RXi Pharmaceuticals)

RXi Pharmaceuticals this week reported its first-quarter financial results, posting a sharply increased net loss on a one-time charge associated with its purchase of the RNAi drug assets of Opko Health in early March.

Quest Diagnostics this week launched a pair of protein biomarker tests for the diagnosis of rheumatoid arthritis.

RXi Pharmaceuticals said this week that it has agreed to acquire all of Opko Health’s RNAi-related assets in exchange for 50 million shares of its common stock, which is worth about $7 million based on RXi’s current stock price.

Opko Health said it has completed the acquisition of the Brazilian pharmaceutical firm Importacao E Exportacao de Produtos Farmaceuticos e Cosmeticos.

Opko Health said this week that it has expanded its collaboration with drugmaker Bristol-Myers Squibb to use its protein biomarker discovery platform to identify markers predictive of patient response to several BMS therapeutics.

NEW YORK (GenomeWeb News) – Opko Health said today that it has expanded a collaboration with Bristol-Myers Squibb to include biomarker discovery for pharmacogenomic tests for use in treating Alzheimer's disease.

NEW YORK (GenomeWeb News) – Opko Health has acquired Prost-Data, a Nashville, Tenn.-based CLIA laboratory doing business under the name OURLab.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.